Akari Therapeutics Plc - ADR

NASDAQ:AKTX   2:37:12 PM EDT
1.67
-0.01 (-0.60%)
Products

Akari Therapeutics Says Completion Of Scientific Advice Meeting With EMA In Advance Of Initiating Phase Iii Pivotal Study Of Nomacopan

Published: 10/01/2020 13:23 GMT
Akari Therapeutics PLC (AKTX) - Akari Therapeutics - Announces Completion of Scientific Advice Meeting With Ema in Advance of Initiating Phase Iii Pivotal Study of Nomacopan.
Akari Therapeutics Plc - Ema Has Agreed to Akari's Proposal for a Phase Iii Randomized Placebo-controlled Study.
Akari Therapeutics - Believes Overlapping Advice Received From Agencies Allows Pivotal Phase Iii Study Design to Satisfy Both FDA & Ema Recommendations.
Akari Therapeutics Plc - Plan to Initiate Phase Iii Study in Both U.S. and Europe During First Half of 2021.